Seattle, Washington 98104


Purpose:

Hip arthroscopy is commonly associated with moderate-to-severe postoperative pain. The purpose of this study is to investigate the analgesic efficacy of preoperative obturator nerve block as measured by postoperative pain scores and postoperative analgesic requirements. The primary outcome will be the patient's first reported pain scores in the post anesthesia care unit (PACU).


Study summary:

RESEARCH DESIGN AND METHODS Patient selection The proposed study will be a prospective randomized placebo-controlled trial. Eligibility criteria will include patients having primary unilateral ambulatory hip arthroscopy for femoral acetabular impingement, age 18 to 65 years, ASA physical status I to III, and ability to follow the protocol. Exclusion criteria: patient refusal, inability to comprehend the consent form, age < 18, and > 65 years of age; contraindications to obturator nerve blockade (pre-existing neuromuscular or peripheral nerve disorder, localized infection, or bleeding disorder); allergy to opioids or local anesthetics; allergy to celecoxib or sulfa medications or nonsteroidal anti-inflammatory medications (NSAIDs); chronic opioid use (> 1 month of 60 mg morphine PO equivalents daily); and, women who are pregnant or breastfeeding. Consent Patients will be enrolled preoperatively in either the orthopedic surgery clinic or through the anesthesia preoperative clinic after the hip arthroscopy surgery is scheduled Randomization, Blinding, and Allocation Study medications will be administered by the primary investigator who will perform or closely supervise all ultrasound-guided obturator nerve blocks. Randomization will be performed with use of computerized random number generator and then each assignment will be placed into an opaque sealed envelope. Upon enrollment into the study and consent obtained, the next sealed envelope (numbered sequentially) will be opened and the patient allocated to either: - Group 1 (Treatment), Ultrasound-guided obturator nerve block: 20 ml ropivacaine 0.5% - Group 2 (Placebo), Ultrasound-guided saline placebo block: 5 mL sterile saline 0.9% The primary investigator will not be involved in any subsequent postoperative data collection. The sub-investigators will perform all subsequent data collection and will be blinded to group allocation. Intervention Following randomization, the principle investigator will perform the block procedure 30 minutes prior to expected transfer back to the operating room. Anesthetic care All intraoperative anesthetic care will be standardized as well, including general endotracheal anesthesia induction using propofol 1.5-2mg/kg IV, succinylcholine 1-1.5mg/kg IV or rocuronium 0.6-1mg/kg IV (based on the clinical discretion of the blinded anesthesia provider). In order to provide adequate intraoperative analgesia for both groups for the expected duration of the procedure, 1 mg of intravenous hydromorphone will be administered 10 minutes prior to surgical incision. No further intraoperative opioids will be administered. Neuromuscular blockade will be maintained with rocuronium as indicated by surgical requirements and titrated by neuromuscular monitoring, and reversed in standard fashion prior to emergence from general anesthesia. At the end of the procedure, the surgeon will inject ropivacaine 0.25% 30 mL in each of the 2 arthroscopic portal sites for a total of 60 ml ropivacaine 0.25% in all subjects as is standard practice for all hip arthroscopy patients. Subjects will be given a log to record their postoperative pain scores and oxycodone consumption for the 1st 24 hours after discharge. Outcomes The primary outcome will be the pain immediately upon arrival to the post anesthesia care unit. This will be measured by an 11-point numerical rating scale (NRS 0 = no pain, and 10 = worst pain imaginable). Secondary outcomes will include NRS pain scores at additional time frames for pain score self-assessments will include: 1. 3-4 hours after arriving home 2. Within 1 hour prior to going to sleep 3. Within 1 hour after waking up the following day. 4. 24 hours after surgery Additional secondary outcomes will also include: cumulative 24-hour postoperative opioid consumption, percentage of patients with postoperative nausea and vomiting, sleep disturbance (difficulty going to sleep or waking up from sleep due to postoperative pain). Expected Time Frame Typically, 4-5 hip arthroscopies per week are performed. Thus the expected timetable for recruitment will take at least 6-12 months


Criteria:

Inclusion Criteria: - Primary unilateral ambulatory hip arthroscopy - Age 18 to 65 years - ASA physical status I to III - Ability to follow the protocol. Exclusion Criteria: - Age <18 or >65 years of age - Contraindications to peripheral nerve blockade - Allergy to opioids or local anesthetics - Allergy to sulfa medications or nonsteroidal anti-inflammatory medications - Chronic opioid - Patient refusal


NCT ID:

NCT02346357


Primary Contact:

Principal Investigator
Francis Salinas, MD
Virginia Mason Medical Center

Francis Salinas, MD
Phone: 206-223-6980
Email: Francis.Salinas@virginiamason.org


Backup Contact:

Email: stanley.yuan@virginiamason.org
Stan Yuan, MD
Phone: 206-223-6980


Location Contact:

Seattle, Washington 98104
United States

Francis Salinas, MD
Phone: 206-223-6980
Email: Francis.Salinas@virginiamason.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.